Vorapaxar has bleeding risk. Stem cell drug approved for advanced trial. Print E-mail
By BioMedReports.com Staff   
Wednesday, 19 January 2011 20:44
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 19, 2011.

Vorapaxar has bleeding risk.  -  An independent committee, after monitoring clinical trials of Vorapaxar, determined it was inappropriate for patients with a history of strokes due to bleeding.  Vorapaxar, which was meant to prevent heart attacks and strokes, or their recurrence, nearly erased $8 billion from Merck & Co.'s (NYSE:MRK) market value.   Merck informed investigators of the Data and Safety Monitory Board's recommendations, including observation of "an increase in intracranial hemorrhage in patients with a history of stroke that is not outweighed by their considerations of potential benefit."


Pluristem stem cell drug approved for advanced trial.  - Pluristem Therapeutics (NASDAQ:PSTI), Israeli stem cell therapy company, has U.S. and European approval to conduct an advanced trial for its treatment of peripheral artery disease, a degenerative disorder. Pluristem will also conduct a Phase II trial to test its treatment on an earlier stage of the disease, placing it on track for a preventative treatment in addition to treating amputation-destined cases. The treatment for both stages of the disease targets a 20 million patient market.


Also Wednesday:


BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.

BioMed Realty Trust, Inc. (NYSE:BMR) today announced the tax treatment of its 2010 distributions

Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results for the fourth quarter and year ended December 31, 2010 on Wednesday, February 2, at 8:00 a.m. ET.

Gen-Probe Incorporated (Nasdaq:GPRO) announced today that the Company will release its fourth quarter and full year 2010 financial results on Tuesday, February 15, 2011 at approximately 4:00 p.m. Eastern Time (ET).

LifeVantage Corporation (OTC Bulletin Board:LFVN), the maker of science-based solutions to oxidative stress, announced preliminary unaudited net revenue for its second fiscal quarter of 2011.

Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today that it has entered into a final product development and production agreement for the manufacture of its AsepticSure™ Advanced Oxidative Sterilization Processes, with ADA Innovations of Toronto, Canada.

Nationwide Health Properties, Inc. (NYSE:NHP) announced today the tax treatment for its 2010 dividend distributions.

Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has been selected to present at the 8th Annual BIO Asia International Partnering Conference January 24-25, 2010 in Tokyo, Japan.

Rural/Metro Corporation (NASDAQ: RURL), a leading provider of ambulance and private fire protection services, will release results for its fiscal 2011 second quarter ended December 31, 2010 before the opening of the stock markets on February 9, 2011.

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces that, Preferred Distribution, Inc. its medical and dental supplies distribution subsidiary ("Preferred"), (www.preferreddist.com) is targeting the second quarter of 2011 for the launch of its new pharmaceutical distribution division.

Unity Management Group, Inc. (PINKSHEETS: UYMG) "UNITY" (or the "Company"), a Health Resource Company specializing in Physician and Hospital Practice Management, Medical Discount Plans, Business Services, Billing Software and Technologies, along with Pharmacy Instrumentation, and Calibration.

ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a Binding Letter of Intent ("Agreement") with Exciton Technologies Inc. ("Exciton") to develop and market a product that will combine Altrazeal® with Exciton's proprietary exSALT™ Antimicrobial Technology.

UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the Company will commence shipments this week to its newest Asian distributor, Ormed Systems ("Ormed") of Mumbai, India, for distribution to the Medical and Hospitality marketplace throughout the subcontinent.

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has established a captive lease program with Coastal Leasing, Inc. to provide a financing option for purchase of its PD2i Analyzer™.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter